Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women

Abstract

This study indicated that ZOL could increase BMD and reduce fracture risk in women with osteoporosis over a 2-year follow-up period, and was not associated with any serious drug-related adverse effects.